EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes

Muhammed Dogukan Aksu, Jayla T Millender, Chantal E McCabe, Ryan D Watkins, Jennifer A Yonkus, EeeLN H Buckarma, Nathan W Werneburg, Daniel R O'Brien, Rondell P Graham, Gregory J Gores, Rory L Smoot, Caitlin B Conboy

Cellular Oncology · 2025

DOI: 10.1007/s13402-025-01133-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Muhammed Dogukan Aksu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Hauptthemen laut MEDLINE: Hepatocytes, Adaptor Proteins, Signal Transducing, Carcinogenesis, Tyrosine. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Center for Cell Signaling in Gastroenterology, Mayo Clinic, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesAdaptor Proteins, Signal TransducingCarcinogenesisTyrosineAnimalsPhosphorylationYAP-Signaling ProteinsMice, Inbred C57BLTranscription FactorsHumansCell Line, TumorLiver NeoplasmsSignal TransductionCholangiocarcinomaCell Cycle ProteinsMiceCarcinoma, HepatocellularPhosphoproteins

Stichwörter der Autor:innen

HCCLineage commitmentLiver plasticityPhosphorylationYes-associated protein (YAP)cHCC-CCAiCCA

Substanzen

YAP-Signaling ProteinsAdaptor Proteins, Signal TransducingYap1 protein, mouseTranscription FactorsCell Cycle ProteinsTyrosinePhosphoproteins

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
  • Division of Gastroenterology & Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Division of Hepatobiliary & Pancreas Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

Förderung

  • NIH HHS
  • Center for Cell Signaling in Gastroenterology, Mayo Clinic
  • National Institutes of Health
  • Fifth District Eagles Cancer Telethon
  • Cholangiocarcinoma Foundation

Zitieren

APA

Aksu, M. D., Millender, J. T., McCabe, C. E., Watkins, R. D., Yonkus, J. A., Buckarma, E. H., Werneburg, N. W., O'Brien, D. R., Graham, R. P., Gores, G. J., Smoot, R. L., & Conboy, C. B. (2025). The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes. Cellular Oncology. https://doi.org/10.1007/s13402-025-01133-x

Vancouver

Aksu MD, Millender JT, McCabe CE, Watkins RD, Yonkus JA, Buckarma EH, et al. The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes. Cellular Oncology. 2025. doi:10.1007/s13402-025-01133-x

BibTeX
@article{Aksu2025,
  author = {Aksu, Muhammed Dogukan and Millender, Jayla T and McCabe, Chantal E and Watkins, Ryan D and Yonkus, Jennifer A and Buckarma, EeeLN H and Werneburg, Nathan W and O'Brien, Daniel R and Graham, Rondell P and Gores, Gregory J and Smoot, Rory L and Conboy, Caitlin B},
  title = {The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-025-01133-x}
}
Kostenlos starten →